Compare Biocon Ltd with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs AUROBINDO PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON AUROBINDO PHARMA BIOCON /
AUROBINDO PHARMA
 
P/E (TTM) x 32.7 17.1 190.5% View Chart
P/BV x 4.2 3.5 119.9% View Chart
Dividend Yield % 0.2 0.3 77.9%  

Financials

 BIOCON    AUROBINDO PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
AUROBINDO PHARMA
Mar-19
BIOCON /
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs707830 85.2%   
Low Rs554527 105.1%   
Sales per share (Unadj.) Rs91.9333.9 27.5%  
Earnings per share (Unadj.) Rs16.740.4 41.4%  
Cash flow per share (Unadj.) Rs24.251.8 46.7%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %0.20.4 43.0%  
Book value per share (Unadj.) Rs101.6237.1 42.9%  
Shares outstanding (eoy) m600.00585.91 102.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.92.0 337.6%   
Avg P/E ratio x37.716.8 224.4%  
P/CF ratio (eoy) x26.113.1 199.0%  
Price / Book Value ratio x6.22.9 216.8%  
Dividend payout %6.06.2 96.6%   
Avg Mkt Cap Rs m378,330397,569 95.2%   
No. of employees `0006.117.9 34.3%   
Total wages/salary Rs m11,65325,849 45.1%   
Avg. sales/employee Rs Th8,994.310,956.9 82.1%   
Avg. wages/employee Rs Th1,900.71,447.7 131.3%   
Avg. net profit/employee Rs Th1,635.31,324.3 123.5%   
INCOME DATA
Net Sales Rs m55,144195,636 28.2%  
Other income Rs m1,4441,553 93.0%   
Total revenues Rs m56,588197,189 28.7%   
Gross profit Rs m15,88339,519 40.2%  
Depreciation Rs m4,4786,680 67.0%   
Interest Rs m7092,626 27.0%   
Profit before tax Rs m12,14031,767 38.2%   
Minority Interest Rs m927 33.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m2,1237,269 29.2%   
Profit after tax Rs m10,02623,645 42.4%  
Gross profit margin %28.820.2 142.6%  
Effective tax rate %17.522.9 76.4%   
Net profit margin %18.212.1 150.4%  
BALANCE SHEET DATA
Current assets Rs m48,228153,645 31.4%   
Current liabilities Rs m30,376120,429 25.2%   
Net working cap to sales %32.417.0 190.7%  
Current ratio x1.61.3 124.4%  
Inventory Days Days68135 50.5%  
Debtors Days Days8664 134.2%  
Net fixed assets Rs m64,130103,909 61.7%   
Share capital Rs m3,000586 512.0%   
"Free" reserves Rs m57,980138,322 41.9%   
Net worth Rs m60,980138,908 43.9%   
Long term debt Rs m15,7661,800 876.1%   
Total assets Rs m121,924264,544 46.1%  
Interest coverage x18.113.1 138.4%   
Debt to equity ratio x0.30 1,995.8%  
Sales to assets ratio x0.50.7 61.2%   
Return on assets %8.89.9 88.7%  
Return on equity %16.417.0 96.6%  
Return on capital %16.823.8 70.3%  
Exports to sales %28.149.6 56.7%   
Imports to sales %18.918.8 100.4%   
Exports (fob) Rs m15,50697,091 16.0%   
Imports (cif) Rs m10,39936,741 28.3%   
Fx inflow Rs m15,50697,316 15.9%   
Fx outflow Rs m10,39940,589 25.6%   
Net fx Rs m5,10756,727 9.0%   
CASH FLOW
From Operations Rs m11,54616,220 71.2%  
From Investments Rs m-7,138-28,768 24.8%  
From Financial Activity Rs m-2,41719,191 -12.6%  
Net Cashflow Rs m2,1036,656 31.6%  

Share Holding

Indian Promoters % 40.4 54.1 74.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 8.0 105.7%  
FIIs % 10.7 27.7 38.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.2 195.1%  
Shareholders   109,995 69,601 158.0%  
Pledged promoter(s) holding % 0.0 8.6 0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   SHASUN PHARMA  DR. REDDYS LAB  GSK PHARMA  FULFORD INDIA  WYETH LTD  

Compare BIOCON With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Rally; Infosys & Axis Bank Top Gainers(12:30 pm)

Share markets in India have extended early gains and are presently trading on a strong note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

How We Made 10%+ Profits Overnight(Fast Profits Daily)

Jul 3, 2020

A simple trade in natural gas delivered more than 10% overnight. Here's how we did it...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jul 15, 2020 01:07 PM

TRACK BIOCON

BIOCON - WYETH LTD COMPARISON

COMPARE BIOCON WITH

MARKET STATS